富科伊丹改善了小鼠手术后阴茎的肠周位功能
Baoguo He1, Zhenming Zhu1, Zibin Tian1
1Department of Gastroenterology, the Affiliated Hospital of Qingdao University, Qingdao, Shandong, 266000, China.
Naunyn-Schmiedeberg's archives of pharmacology
|November 7, 2024
概括
富科伊丹通过改善肠道运动性,有效治疗大鼠的手术后阴茎 (POI). 这种天然化合物减少了炎症和氧化应激,为POI提供了潜在的治疗策略.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
- 细胞生物学 细胞生物学
背景情况:
- 手术后阴道 (POI) 显著影响患者的康复,其特点是肠道运动能力受损.
- 棕藻中的多糖化合物fucoidan对POI的治疗潜力仍然未被探索.
研究的目的:
- 在大鼠模型中调查富可伊丹在改善POI方面的疗效.
- 阐明福科伊丹对肠道运动的作用的潜在机制.
主要方法:
- 建立了POI的老鼠模型,以评估口服富可伊丹预治疗的影响.
- 评估的关键参数包括第一次排便的时间,食物摄入量,小肠推进率和运动指数 (MI%).
- 在体外研究中检查了光滑肌肉收缩性,而免疫组织化学和分子分析评估了炎症标志物和信号通路 (TrkB/ERK1/2/Akt).
主要成果:
- 富科伊丹预治疗显著改善了肠道运动性,减少了第一次排便的时间,并增加了POI大鼠的食物摄入量,推进率和MI%.
- 富科伊丹增强了肠道光滑肌肉对卡巴胆的收缩反应,并减少了巨细胞的透.
- 机械上,富可伊丹显示出抗炎和抗氧化作用,使炎症因子,马隆迪甲 (MDA),超氧化失调酶 (SOD) 和谷氨 (GSH) 水平正常化,并调节TrkB/ERK1/2/Akt信号传输.
结论:
- 富科伊丹有效地缓解POI诱导的小鼠肠移动性的损伤.
- 富科伊丹的治疗益处归因于其抗炎和抗氧化特性.
- 富科伊丹的作用可能涉及TrkB/ERK1/2/Akt信号通路,这表明POI的新疗法.
相关概念视频
01:21Drugs for Treatment of Constipation-Predominant IBS
136
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
136
01:21Inflammatory Bowel Disease V: Surgical Management
122
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
122
01:17Drugs for Treatment of Diarrhea-Predominant IBS
147
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
147